Cue Biopharma, Inc. Marketable Securities
Cue Biopharma, Inc. (CUE) had Marketable Securities of $27.10 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Balance Sheet › Assets
us-gaap:MarketableSecurities · last filed 2026-03-16
- 2025-12-31: Marketable Securities $27.10M.
- 2025-09-30: Marketable Securities $18.70M.
- 2025-06-30: Marketable Securities $27.50M.
- 2025-03-31: Marketable Securities $13.10M.
| Period end | Marketable Securities |
|---|---|
| 2025-12-31 | $27.10M 10-K · filed 2026-03-16 |
| 2025-09-30 | $18.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $27.50M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $13.10M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $22.50M 10-K · filed 2025-03-31 |
| 2024-09-30 | $32.40M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $30.00M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $41.00M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $48.50M 10-K · filed 2024-03-28 |
| 2023-09-30 | $54.69M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $57.89M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $66.20M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $76.30M 10-K · filed 2023-03-21 |
| 2022-09-30 | $59.18M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |